Sfoglia per AUTORE
ROCCO D
Collezione AOU San Luigi di Orbassano

  

Items : 10

A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify(®) Mutation Profiler. in Oncology and therapy / Oncol Ther. 2025 Mar;13(1):115-130. doi: 10.1007/s40487-024-00316-0. Epub 2024 Nov 28.
2025
AOU San Luigi di Orbassano

Pepe F; Russo G; Barraco N; Bono M; Listì A; Righi L; de Biase D; Maloberti T; Scimone C; Palumbo L; Rocco D; Roscigno G; Gallo E; Buglioni S; Coco M; Muscarella LA; Troncone G; Malapelle U;

RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. in Personalized medicine / Per Med. 2022 Sep;19(5):395-401. doi: 10.2217/pme-2022-0020. Epub 2022 Jul 8.
2022
AOU San Luigi di Orbassano

Luca C; Pepe F; Pisapia P; Iaccarino A; Righi L; Listì A; Russo G; Campione S; Pagni F; Nacchio M; Conticelli F; Russo M; Fabozzi T; Vigliar E; Bellevicine C; Rocco D; Laudati S; Iannaci G; Daniele B; Gridelli C; Cortinovis DL; Novello S; Molina-Vila MA; Rosell R; Troncone G; Malapelle U;

Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jan;169:103536. doi: 10.1016/j.critrevonc.2021.103536. Epub 2021 Nov 18
2022
AOU San Luigi di Orbassano

Malapelle U; Pilotto S; Reale ML; Passiglia F; Pisapia P; Pepe F; Belluomini L; Galetta D; Cortinovis D; Tiseo M; Passaro A; Seminati D; Pagni F; Parra HS; Migliorino MR; Rocco D; Troncone G; Novello S; Malapelle U; Pilotto S; Reale ML; Passiglia F; Pisapia P; Pepe F; Belluomini L; Galetta D; Cortinovis D; Tiseo M; Passaro A; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Porzio G; Cannita K; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Ricciardi S; Migliorino MR; Landi L; Minuti G; Tuzi A; Bordi P; Russano M; Cantini L; Santini D; Citarella F; Zoratto F; Filetti M; Mansueto G; Di Marino P; Grassadonia A; Inno A; et alii...

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
2020
AOU San Luigi di Orbassano

Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May
2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...

Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2020 Jul 20;12:1758835920915983. doi: 10.1177/1758835920915983. eCollection 2020
2020
AOU San Luigi di Orbassano

Gelsomino F; Lamberti G; Tiseo M; Rocco D; Pasello G; Cecere FL; Chella A; Grilli G; Mandruzzato M; Tognetto M; Garassino MC; Macerelli M; Novello S; Roila F; Colantonio I; Grossi F; Fiorentino M; Ardizzoni A;